In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Kisqali, Pluvicto Drive Novartis (NVS ... mounting non-interest expenses, significant exposure to commercial loans, and deteriorating asset quality will likely hurt WaFd's financials.

Kisqali (ribociclib ... The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from ...

A daily pill, Kisqali is a cyclin-dependent kinase 4 ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

Kisqali was recently approved to reduce the ... With no meaningful pipeline events this year from Novartis, the investor focus is on commercial execution. And it should not be lacking in the ...

This update reflects Kisqali’s efficacy in both node-positive disease and ... patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...